GMA 302
Alternative Names: GMA-302Latest Information Update: 27 Nov 2020
At a glance
- Originator Gmax Biopharm
- Class Antihypertensives; Monoclonal antibodies
- Mechanism of Action Endothelin B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Hypertension; Pulmonary hypertension
Most Recent Events
- 03 Nov 2020 GMA 302 is available for licensing as of 03 Nov 2020. http://www.gmaxbiopharm.com/job.html
- 03 Nov 2020 Early research in Hypertension in China (Parenteral) before November 2020 (Gmax Biopharm pipeline, November 2020)
- 03 Nov 2020 Early research in Pulmonary hypertension in China (Parenteral) before November 2020 (Gmax Biopharm pipeline, November 2020)